XyloCor Therapeutics Company
developed lead gene therapy candidate, XC001, as a vehicle to stimulate and augment the native tissue revascularization mechanisms specifically targeting individuals who have demonstrated an inadequate endogenous self-revascularization response to ischemia.
Technology:
Cardiovascular Disorders
Industry:
Gene Therapy
Headquarters:
Pennsylvania, United States
Founded Date:
2013
Funding Status:
Early Stage Venture
Estimated Revenue:
$1M to $10M
Register and Claim Ownership